Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts

M. Frueh*, C. M. Panje, M. Reck, F. Blackhall, R. Califano, F. Cappuzzo, B. Besse, S. Novello, P. Garrido, E. Felip, M. O'Brien, L. Paz Ares, F. de Marinis, Virginie Westeel, D. De Ruysscher, P. M. Putora

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)6-11
Number of pages6
JournalLung Cancer
Volume146
DOIs
Publication statusPublished - Aug 2020

Keywords

  • Small cell lung cancer (SCLC)
  • Second-line chemotherapy
  • Decision making
  • Objective consensus
  • OPEN-LABEL
  • PHASE-III
  • TOPOTECAN
  • CHEMOTHERAPY
  • MULTICENTER
  • RECHALLENGE
  • ETOPOSIDE
  • SELECTION
  • OUTCOMES
  • IASLC

Cite this